


Zhifei Biologicals is an internationalized, whole-industry chain engaged, high-tech biopharmaceutical company integrating the research and development, production, sales, distribution, import and export of vaccines and biological products.



300+

Municipal Level

2000+

Research and Production Team

2600+

Districts and Counties


3400+

Sales Team

30000+

PHC Points

DISEASE PREVENTION



9 Major Technology Platforms

8 R&D Candidate Matrices






Zhirui Investment is an equity investment company jointly funded by Zhifei Biologicals and its controlling shareholders to construct Zhirui Biomedical Industrial Park. It is divided into research, development and incubation center, antibody drug industrialization center, diabetes drug industry center, and drug evaluation center.

4 Major Target Fields
180+ Patents Applied

DISEASE TREATMENT



Robust pipeline targeting 4 diseases areas with a few to be launched soon

Matrix	Project Name	INDICATION	IND	Phase I	Phase II	Phase III	NDA
Autoimmune diseases	Xeligekimab* (IL-17A)	Plaque psoriasis; Spondylarthritis; Lupus nephritis					Estimated approval 2024
	GR1802 Injection (IL-4Rα)	Atopic dermatitis, chronic sinusitis with nasal polyps, asthma					
	GR1603 Injection (IFNAR1)	Systemic lupus erythematosus (SLE)					
	GR2002 Injection (TSLP)	Asthma, COPD, etc.					
Diabetes	Liraglutide injection	Type 2 Diabetes Mellitus					Estimated approval 2025
	Insulin degludec injection	Type 2 Diabetes Mellitus					Estimated approval 2025
	Semaglutide injection	Type 2 Diabetes Mellitus					Estimated approval 2026
	Insulin aspart Injection	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus					Estimated approval 2026
	PEGylated recombinant human insulin injection	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus					
	Insulin degludec/insulin aspart injection	Type 2 Diabetes Mellitus					
Infectious Disease	GR1801 Injection (RABV)	Passive immunization after suspected exposure to rabies virus					
	GR2001 Injection	Passive immunity against tetanus					
Tumor	pCAR-19B cell autotransfusion preparation	Acute lymphoblastic leukemia					Estimated approval 2024
	GR1803 Injection (CD3*BCMA)	Multiple myeloma					
	GR1901 Injection (CD3*CD123)	Acute myeloid leukemia(AML)					
	C-4-29 cell preparation	Multiple myeloma; Renal cell carcinoma					
	C-13-60 cell preparation	Colorectal, gastric and esophageal cancer					